Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mary Boudreau

Nurse Practitioner, Primary Care Mason, MI Nurse Practitioner

NPI 1730523598 CMS profile 10449454

790 E Columbia St, Mason, MI 48854

Open in the dashboard

General payments

$8,528

340 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Boudreau of Mason, MI is reported in the CMS Open Payments database as having received $8,528 across 340 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,257 132
2024 General $2,302 97
2023 General $1,632 54
2022 General $1,026 39
2021 General $310 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Boudreau
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Mary Boudreau were reported at $3,257. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Mary Boudreau Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $310 $137 $39–$445 $132
2022 $1,026 $139 $44–$421 $149
2023 $1,632 $163 $53–$481 $160
2024 $2,302 $176 $54–$511 $164
2025 $3,257 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $1,974 37 payments
  2. ViiV Healthcare Company $1,658 68 payments
  3. GlaxoSmithKline, LLC. $574 25 payments
  4. Pfizer Inc. $562 27 payments
  5. Novo Nordisk Inc $469 27 payments
  6. Merck Sharp & Dohme Corporation $466 23 payments
  7. Lilly USA, LLC $384 19 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $247 14 payments
  9. Otsuka America Pharmaceutical, Inc. $181 8 payments
  10. Janssen Biotech, Inc. $169 8 payments
  11. Other $1,844 84 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,517 339 payments
  2. Education $11 1 payment
Products named General payments · program years 2021–2025
  1. DOVATO $814 35 payments
  2. PIFELTRO $428 21 payments
  3. DELSTRIGO $352 17 payments
  4. CABENUVA $319 12 payments
  5. MOUNJARO $314 14 payments
  6. NURTEC ODT $309 15 payments
  7. ZAVZPRET $290 11 payments
  8. TRELEGY ELLIPTA $258 14 payments
  9. APRETUDE $252 10 payments
  10. Kerendia $247 14 payments
  11. Other $5,562 250 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 171 drugs

Part D claims

10,041

Median for Nurse Practitioner: 389

Drug cost

$1,992,597

Median for Nurse Practitioner: $21,885

Branded share of claims

23.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 129 $498,741
Cabenuva Cabotegravir/Rilpivirine Brand 38 $214,601
Eliquis Apixaban Brand 142 $157,196
Dovato Dolutegravir Sodium/Lamivudine Brand 42 $120,316
Descovy Emtricitabine/Tenofov Alafenam Brand 36 $76,498
Tivicay Dolutegravir Sodium Brand 29 $74,931
Ozempic Semaglutide Brand 55 $70,668
Juluca Dolutegravir/Rilpivirine Brand 17 $57,977
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 14 $57,867
Xarelto Rivaroxaban Brand 44 $57,496

The 10 drugs with the highest cost, of 171 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$49,728

Medicare's payments for the services billed

Medicare patients

298

Average age 76

Services billed

1,411

175 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Chronic kidney disease 38%
Diabetes 37%
Depression 34%
Ischemic heart disease 29%
COPD 24%
Heart failure 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DOVATO
$239 42 —
CABENUVA
$162 38 —
JARDIANCE
$141 25 —
Kerendia
$108 — —
APRETUDE
$100 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

340 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record